Pope Leo XIV said Sunday he’s set to have surgery within the next few days to remove a lung nodule, marking the pontiff's ...

The Japanese Patent Office has signalled its intention to grant patent protection for bioAffinity Technologies’ noninvasive ...

It is hoped the prospective sale provides a haven for wildlife in an urban area.

As global pharmaceutical companies face the expiration of patents for their original drugs, competition in the development of ...

The number of ordering physicians increased by 89% in Q3 2026 compared to Q3 2025. Physicians who ordered CyPath Lung through Q3 2025 continued to expand utilization of the test, with sales volume ...

C EGFR T790M gene variant face roughly 25 times the lung cancer risk of noncarriers, according to the largest-yet study of ...

DMedical shares gained 4.44% as investors supported the company's international expansion of CT:VQ, while questions remain over hospital adoption, revenue growth and reimbursement.

The FDA has granted two Breakthrough Therapy Designations to telisotuzumab adizutecan (Temab-A, also known as ABBV-400), an ...

Bipartisan legislation that would establish a statewide lung cancer screening awareness and referral program for first ...

Smoking cessation in lung cancer screening improved significantly when financial incentives were added to usual care and free ...

Some facial changes are viewed differently in traditional Chinese medicine (TCM), and a few can signal the need for prompt care.

The companies’ nationwide federal healthcare distribution agreement is intended to expand government and agency access to CyPath Lung, bioAffinity Technologies’ noninvasive test for lung cancer, via ...